Seelos Therapeutics (SEEL.Q) investor relations material

Executive summary

• Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on CNS and rare disorders, with lead programs SLS-002 (intranasal ketamine for suicidality in MDD) and SLS-005 (IV trehalose for ALS and SCA).

• The company announced a strategic focus on mental health and a 33% workforce reduction in April 2024 to reduce costs and extend cash runway.

• SLS-005 Phase 2/3 ALS trial did not meet primary endpoints but showed efficacy signals in a pre-specified subgroup; SLS-002 Phase II topline data released in September 2023.

• Ongoing business development efforts include exploring partnerships and collaborations, especially leveraging ketamine expertise.

Financial highlights

• As of June 30, 2024, cash was $0.3 million, down from $3.0 million at December 31, 2023; accumulated deficit reached $253.6 million.

• Net income for Q2 2024 was $1.7 million, compared to a net loss of $29.5 million in Q2 2023; net loss for the six months ended June 30, 2024 was $1.0 million, versus $42.9 million loss in the prior year period.

• Operating expenses for Q2 2024 were $3.5 million, down 69% year-over-year, driven by an 89% reduction in R&D expenses and 8% decrease in G&A.

• Cash used in operations for the six months ended June 30, 2024 was $5.6 million, compared to $16.3 million in the prior year period.

• Financing activities provided $2.9 million in the first half of 2024, mainly from equity and warrant issuances.

Outlook and guidance

• Management believes current cash is insufficient to fund operations for one year beyond the filing date, raising substantial doubt about going concern.

• The company must raise additional capital to meet obligations, including a minimum cash covenant on its convertible note by October 31, 2024.

• Strategic focus remains on advancing SLS-002 and SLS-005, with non-essential preclinical work paused.